long intergenic non-protein coding RNA 1908Genealiases: []
Q-omics provides the consensus-scored LINC01908 profile across patient tissues and cancer cell-line models. LINC01908 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01908 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, LINC01908 RNA expression shows 8,620 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LUAD, and UVM as cancer lineages where LINC01908 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01908 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01908 survival associations across molecular data types. LINC01908 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01908 RNA expression–survival associations across cancer types. High LINC01908 expression shows unfavorable associations in ACC, BLCA, READ, BRCA and UVM, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01908 RNA expression.
This table summarizes LINC01908 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01908. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01908 shows lower tumor expression in LUAD, LUSC, BRCA, HNSC and UCEC. The LUAD box plot shows higher LINC01908 RNA expression in normal versus tumor tissue (log2 FC = −0.700, t-test p < 0.001).
This table shows molecular features associated with LINC01908 in patient tissues and cancer cell lines. In patient samples, LINC01908 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
